cephradine-a new cephalosporin in recurrent urinary tract infection

Clicks: 66
ID: 196060
1977
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #169 of 175 articles by views in international islamic university malaysia engineering journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 175 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Out of 866 bacterial isolates grown in significant colony counts from 3 consecutive mid-stream urine samples or from a single sample of urine obtained by suprapubic bladder puncture, 305 isolates (35.22%) were found to be sensitive to Cephradine. It was noted that Gram positive organisms (63.44%) manifested highest sensitivity to this antibiotic. Next in order was E. coli with a sensitivity of 60.54%. The clinical trial revealed a good response in 59.37% and 81.81; of patients with oral and injectable group re-spectively. The maximum response was seen in E. coli infections (89.47%) and Gram positive organisms coming next with 80% re-sponse. No major untoward reactions were noted in patients with or without azotaemia and the antibiotic could be used safely even in presence of renal failure.
Reference Key
vidya1977journalcephradine-a Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal international islamic university malaysia engineering journal
Year 1977
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.